{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T19:58:17Z","timestamp":1784318297067,"version":"3.55.0"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"unspecified","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"CONACYT","award":["2018-000009-01EXTF-00573"],"award-info":[{"award-number":["2018-000009-01EXTF-00573"]}]},{"name":"UCL Institute of Ophthalmology","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Novartis Pharmaceuticals","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,5,31]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report insights on proliferative diabetic retinopathy (PDR) risk modification with repeated antivascular endothelial growth factor (VEGF) injections for the treatment of diabetic macular oedema (DMO) in routine care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Multicentre study (27 UK-National Health Service centres) of patients with non-PDR (NPDR) and DMO. Primary outcome was PDR development. Repeated anti-VEGF injections were modelled as time-dependent covariates using Cox regression and weighted cumulative exposure (WCE) adjusting for baseline diabetic retinopathy (DR) grade, age, sex, ethnicity, type of diabetes and deprivation. PDR incidence rates (IRs) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 2858 DMO anti-VEGF-treated eyes. Anti-VEGF injections showed a protective effect on PDR risk during the most recent 4\u2009weeks from exposure, which rapidly decreased. Mild-NPDR had a lower PDR risk compared with moderate-NPDR (HR 1.99, 95%\u2009CI 1.13 to 3.51, p=0.015) and severe-NPDR (HR 4.63, 95%\u2009CI 2.55 to 8.41, p&lt;0.001). Patients with type 1 diabetes showed an increased PDR risk when compared with patients with type 2 diabetes (HR 2.08, 95%\u2009CI 1.35 to 3.21, p&lt;0.001). And every 5-year increase in age showed a 9% reduction in PDR hazards (p=0.002). The PDR cumulative IR was 4.45 (95% CI 3.89 to 5.09) per 100 person-years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The WCE method is a valuable modelling strategy for repeated exposures in ophthalmology. Injections are protective against PDR predominantly within the most recent 4 weeks. Based on observed data, we show that age and baseline DR severity are relevant predictors of poor outcomes in patients with DMO treated with anti-VEGF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002234","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T08:50:14Z","timestamp":1752655814000},"page":"e002234","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of anti-VEGF treatment for diabetic macular oedema on progression to proliferative diabetic retinopathy: data-driven insights from a multicentre study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3305-4465","authenticated-orcid":false,"given":"Abraham","family":"Olvera-Barrios","sequence":"first","affiliation":[{"name":"Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"University College London Institute of Ophthalmology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watjana","family":"Lilaonitkul","sequence":"additional","affiliation":[{"name":"University College London Global Business School for Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5297-2301","authenticated-orcid":false,"given":"Tjebo F C","family":"Heeren","sequence":"additional","affiliation":[{"name":"Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0339-5063","authenticated-orcid":false,"given":"Assaf","family":"Rozenberg","sequence":"additional","affiliation":[{"name":"Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"Yitzhak Shamir Medical Center, Zerifin, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Thomas","sequence":"additional","affiliation":[{"name":"University College London Institute of Health Informatics, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-2890","authenticated-orcid":false,"given":"Alasdair","family":"Warwick","sequence":"additional","affiliation":[{"name":"University College London Institute of Cardiovascular Science, London, UK"},{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Soomro","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7551-7288","authenticated-orcid":false,"given":"Abdulrahman","family":"Alsaedi","sequence":"additional","affiliation":[{"name":"Ophthalmology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-3734","authenticated-orcid":false,"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[{"name":"Centre for Vision and Vascular Science, Queen's University of Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralabos","family":"Eleftheriadis","sequence":"additional","affiliation":[{"name":"Ophthalmology, King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faruque","family":"Ghanchi","sequence":"additional","affiliation":[{"name":"Ophthalmology, Bradford Royal Infirmary, Bradford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Patwardhan","sequence":"additional","affiliation":[{"name":"Royal Cornwall Hospitals NHS Trust, Cornwall, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-2948","authenticated-orcid":false,"given":"Paul","family":"Taylor","sequence":"additional","affiliation":[{"name":"University College London Institute of Health Informatics, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Tufail","sequence":"additional","affiliation":[{"name":"Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"University College London Institute of Ophthalmology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"A Egan","sequence":"additional","affiliation":[{"name":"Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"University College London Institute of Ophthalmology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2026010721205721000_10.1.e002234.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"2026010721205721000_10.1.e002234.2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2022-321910"},{"key":"2026010721205721000_10.1.e002234.3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaophthalmol.2017.0821","article-title":"Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab","volume":"135","author":"Bressler","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2026010721205721000_10.1.e002234.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.08.048"},{"key":"2026010721205721000_10.1.e002234.5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.oret.2018.02.011","article-title":"Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies","volume":"2","author":"Mitchell","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"2026010721205721000_10.1.e002234.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.25029"},{"key":"2026010721205721000_10.1.e002234.7","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial","volume":"139","author":"Brown","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"2026010721205721000_10.1.e002234.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001007","article-title":"Effect of less aggressive treatment on diabetic retinopathy severity scale scores: analyses of the RIDE and RISE open-label extension","volume":"7","author":"Goldberg","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"key":"2026010721205721000_10.1.e002234.9","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19970315)16:5<505::AID-SIM424>3.0.CO;2-Z"},{"key":"2026010721205721000_10.1.e002234.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.01105.x"},{"key":"2026010721205721000_10.1.e002234.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(13)38012-9"},{"key":"2026010721205721000_10.1.e002234.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00475-5"},{"key":"2026010721205721000_10.1.e002234.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2003.01077.x"},{"key":"2026010721205721000_10.1.e002234.14","unstructured":"GOV.UK . NHS choice framework - what choices are available to you in your NHS care. Available: https:\/\/www.gov.uk\/government\/publications\/the-nhs-choice-framework\/the-nhs-choice-framework-what-choices-are-available-to-me-in-the-nhs [Accessed 08 Aug 2024]."},{"key":"2026010721205721000_10.1.e002234.15","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309313"},{"key":"2026010721205721000_10.1.e002234.16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ajo.2017.05.020","article-title":"The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group: Report 3: Baseline Retinopathy and Clinical Features Predict Progression of Diabetic Retinopathy","volume":"180","author":"Lee","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"2026010721205721000_10.1.e002234.17","unstructured":"Ministry of Housing, Communities, Local Government . English indices of deprivation 2015. 2015."},{"key":"2026010721205721000_10.1.e002234.18","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3701"},{"key":"2026010721205721000_10.1.e002234.19","doi-asserted-by":"crossref","unstructured":"Therneau T , Grambsch PM . Modeling survival data: extending the cox model. 2000.","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"2026010721205721000_10.1.e002234.20","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009945"},{"key":"2026010721205721000_10.1.e002234.21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0167-9473(91)90022-T","article-title":"Information theoretic criteria in non-parametric density estimation: Bias and variance in the infinite dimensional case","volume":"12","author":"Abrahamowicz","year":"1991","journal-title":"Comput Stat Data Anal"},{"key":"2026010721205721000_10.1.e002234.22","doi-asserted-by":"crossref","unstructured":"Harrell FE . Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Springer, 2015.","DOI":"10.1007\/978-3-319-19425-7"},{"key":"2026010721205721000_10.1.e002234.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.01.021"},{"key":"2026010721205721000_10.1.e002234.24","unstructured":"Therneau T , Lumley T . R survival package. R Core Team; 2013."},{"key":"2026010721205721000_10.1.e002234.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001190","article-title":"Simulation of long-term impact of intravitreal anti-VEGF therapy on patients with severe non-proliferative diabetic retinopathy","volume":"8","author":"Nguyen","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"2026010721205721000_10.1.e002234.26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.oret.2018.06.005","article-title":"Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"2026010721205721000_10.1.e002234.27","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s40123-022-00568-x","article-title":"Impact of Intravitreal Anti-VEGF Therapy on Microperimetry of the Retinal Nonperfusion Areas of Patients with Proliferative Diabetic Retinopathy","volume":"11","author":"Parravano","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"2026010721205721000_10.1.e002234.28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamaophthalmol.2022.0052","article-title":"Trends in Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Medicare Part B Fee-for-Service Beneficiaries","volume":"140","author":"Lundeen","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"2026010721205721000_10.1.e002234.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(13)38014-2"},{"key":"2026010721205721000_10.1.e002234.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.9883"},{"key":"2026010721205721000_10.1.e002234.31","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2308"},{"key":"2026010721205721000_10.1.e002234.32","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051594"},{"key":"2026010721205721000_10.1.e002234.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039608","article-title":"Ethnic variation in the prevalence of visual impairment in people attending diabetic retinopathy screening in the United Kingdom (DRIVE UK)","volume":"7","author":"Sivaprasad","year":"2012","journal-title":"PLoS One"},{"key":"2026010721205721000_10.1.e002234.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003683","article-title":"Ethnic disparities in progression rates for sight-threatening diabetic retinopathy in diabetic eye screening: a population-based retrospective cohort study","volume":"11","author":"Olvera-Barrios","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026010721205721000_10.1.e002234.35","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/08820538.2016.1154170","article-title":"Disparities in Adherence to Screening Guidelines for Diabetic Retinopathy in the United States: A Comprehensive Review and Guide for Future Directions","volume":"31","author":"Fathy","year":"2016","journal-title":"Semin Ophthalmol"},{"key":"2026010721205721000_10.1.e002234.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.10.019"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:21:55Z","timestamp":1767849715000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjophth-2025-002234"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002234","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}